Option chain shows key data for M3-Brigade Acquisition's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for M3-Brigade Acquisition.

M3-Brigade Acquisition (NASDAQ:MBAVU) Stock, Option Chain

M3-Brigade Acquisition V Corp is a blank check company.

M3-Brigade Acquisition V Corp

WIIM

ISRG

Intuitive Surgical shares are trading higher after the company reported better-than-expected Q4 financial results.

<p>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $1.79 by 23.46 percent. This is a 38.12 percent increase over earnings of $1.60 per share from the same period last year.  The company reported quarterly sales of $2.41 billion which beat the analyst consensus estimate of $2.25 billion by 7.22 percent.  This is a 25.14 percent increase over sales of $1.93 billion the same period last year.</p>


Earnings

Earnings Beats

News

Intuitive Surgical Q4 2024 Adj EPS $2.21 Beats $1.79 Estimate, Sales $2.41B Beat $2.25B Estimate

<p><strong>CSX</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>CSX missed estimated earnings by 0.0%, reporting an EPS of $0.42 versus an estimate of $0.42.</p>
<p>Revenue was down $140.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.02 in the last quarter, resulting in a 7.000000000000001% drop share price change the following day.</p>
<p>Here's a look at CSX's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.48</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.67B</td>
<td>3.70B</td>
<td>3.66B</td>
<td>3.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.62B</td>
<td>3.70B</td>
<td>3.68B</td>
<td>3.68B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for CSX <a href="https://www.benzinga.com/quote/CSX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CSX Earnings Report: Q4 Overview

<p><strong>Columbia Banking System</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:02 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Columbia Banking System beat estimated earnings by 9.0%, reporting an EPS of $0.71 versus an estimate of $0.65.</p>
<p>Revenue was down $32.04 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.07 which was followed by a 1.0% drop in the share price the next day.</p>
<p>Here's a look at Columbia Banking System's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.62</td>
<td>0.57</td>
<td>0.53</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.67</td>
<td>0.65</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>481.03M</td>
<td>475.95M</td>
<td>480.36M</td>
<td>526.68M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>496.38M</td>
<td>472.15M</td>
<td>473.72M</td>
<td>519.16M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Columbia Banking System <a href="https://www.benzinga.com/quote/COLB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COLB

Recap: Columbia Banking System Q4 Earnings

<p><strong>Texas Instruments</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported its Q4 earnings results on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Texas Instruments beat estimated earnings by 8.0%, reporting an EPS of $1.3 versus an estimate of $1.2.</p>
<p>Revenue was down $70.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.09 which was followed by a 4.0% increase in the share price the next day.</p>
<p>Here's a look at Texas Instruments's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>1.07</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.47</td>
<td>1.22</td>
<td>1.20</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>4.12B</td>
<td>3.82B</td>
<td>3.61B</td>
<td>4.12B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>4.15B</td>
<td>3.82B</td>
<td>3.66B</td>
<td>4.08B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Texas Instruments management provided guidance for Q1 2025, expecting earnings between $0.94 and $1.16 per share.</p>
<p>To track all earnings releases for Texas Instruments <a href="https://www.benzinga.com/quote/TXN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Texas Instruments Earnings Analysis: Q4 Recap

<p>Community West Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBC#NASDAQ">CWBC</a>) reported quarterly earnings of $0.36 per share. This is a 28 percent decrease over earnings of $0.50 per share from the same period last year.</p>


CWBC

Community West Bancshares Q4 EPS $0.36 Down From $0.50 YoY

<p>Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.65 by 9.23 percent.&nbsp;</p>


Columbia Banking System Q4 2024 Adj EPS $0.71 Beats $0.65 Estimate

CSX shares are trading lower following mixed Q4 financial results.

<ul>
<li>"TI's first quarter outlook is for revenue in the range of $3.74 billion to $4.06 billion and earnings per share between $0.94 and $1.16. We now expect our 2025 effective tax rate to be about 12%."</li>
</ul>


Guidance

Texas Instruments Q1 Outlook For Revenue In The Range Of $3.74B-$4.06B Vs $3.874B Est.; EPS Between $0.94-$1.16 Vs $1.17 Est; Now Expect Our 2025 Effective Tax Rate To Be About 12%

<p>Business First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.49 by 4.08 percent. This is a 22.73 percent decrease over earnings of $0.66 per share from the same period last year.</p>


BFST

Business First Bancshares Q4 2024 Adj. EPS $0.51 Beats $0.49 Estimate

NVNI

Nuvini Receives Written Notice That It Regained Compliance With Nasdaq Minimum Bid Price Listing Requirements

<p>CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) reported quarterly earnings of $0.42 per share which met the analyst consensus estimate.  The company reported quarterly sales of $3.540 billion which missed the analyst consensus estimate of $3.576 billion by 1.00 percent.  This is a 3.80 percent decrease over sales of $3.680 billion the same period last year.</p>


Earnings Misses

CSX Q4 2024 Adj. EPS $0.42, Inline, Sales $3.540B Miss $3.576B Estimate

<p>Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.20 by 8.33 percent. This is a 12.75 percent decrease over earnings of $1.49 per share from the same period last year.  The company reported quarterly sales of $4.01 billion which beat the analyst consensus estimate of $3.87 billion by 3.43 percent.  This is a 1.72 percent decrease over sales of $4.08 billion the same period last year.</p>


Texas Instruments Q4 EPS $1.30 Beats $1.20 Estimate, Sales $4.01B Beat $3.87B Estimate

<p>App stores from <strong>Alphabet </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and<strong> Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) currently don&#8217;t allow users to download <strong>TikTok</strong> due to uncertainty about whether it will be permanently <a href="https://www.benzinga.com/25/01/43076609/tiktok-back-online-in-us-after-trump-vows-monday-executive-order">banned in the U.S.</a></p>
<p>But a person without TikTok has at least one route to getting the app. </p>
<p><strong>What Happened</strong>: As <a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone">Benzinga recently predicted</a>, <strong>eBay Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) has phones already with TikTok on them up for auction.</p>
<p>A quick look at eBay Thursday with the search "phone with TikTok" generated over 21,000 results. Many of the listings do not have bids with prices ranging from hundreds of dollars to thousands. Sorting the results by sold <a href="https://www.ebay.com/sch/i.html?_nkw=phone+with+tiktok&amp;_sacat=0&amp;_from=R40&amp;_sop=1&amp;rt=nc&amp;LH_Sold=1&amp;LH_Complete=1">items</a>, there are over 100 items that have actually sold.</p>
<p>Here are some of the latest sales at the time of writing Thursday:</p>
<ul>
<li>iPhone 11: $125.99</li>
<li>iPhone 15 Pro Max: Unknown price, took best offer from a $25,000 listing price</li>
<li>iPhone 15: $100.00</li>
<li>iPhone 15 Pro Max: $600.00</li>
<li>Samsung Galaxy S24: $4.00</li>
</ul>
<p>Going back through the listings there are several high sales prices, which include:</p>
<ul>
<li>iPhone 16 Pro Max Gold Gray: $12,999.99</li>
<li>Samsung Ultra 3 Note: $5,500</li>
<li>iPhone 15 Plus: $1,200</li>
<li>iPhone 15 Pro Max: $10,000</li>
<li>iPhone 15 Pro Max: $11,000</li>
</ul>
<p>The eBay sale prices are what an auction listing closed at or what someone agreed to pay. The big question is whether people are actually paying for the phones and having them shipped. Some of the winning bidders had relatively new or seldom used eBay accounts based on the feedback score, an eBay metric that ranks buyers and sellers.</p>
<p>There is also risk for phone buyers as they can use their ID to sign into apps, but any restores or backups could disrupt the app. Essentially, buying a phone with TikTok could be a waiting game for the app to be banned and ByteDance to turn off access in America or until the user messes up the app settings. There is also the risk of buying the phone only for the TikTok  ban to end and everyone being able to download the app for free again.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/12/42654769/tiktok-ban-under-trump-president-elect-wants-to-keep-months-after-pelosi-said-follow-the-money">TikTok Ban Under Trump? President-Elect Reconsiders As Pelosi Says &#8216;Follow The Money&#8217;</a></strong></p>
<p><strong>Why It's Important</strong>: The U.S. ban of <strong>TikTok </strong>could mean missed revenue opportunities for content creators. TikTok users might have another revenue source while they await the outcome of the pending ban.</p>
<p>President <strong>Donald Trump</strong> <a href="https://www.benzinga.com/general/social-media/25/01/43088960/trump-suspends-us-tiktok-ban-for-75-days-with-executive-order-but-legal-and-market-uncertain">issued an executive order</a> to temporarily stop the ban of TikTok in the U.S.</p>
<p>While the order kept TikTok parent <strong>ByteDance </strong>from ending the use of TikTok in the U.S., the outcome of the social media app remains uncertain.</p>
<p>Trump recently proposed that the U.S. should have a 50% stake in a joint venture, the <a href="https://apnews.com/article/tiktok-ban-executive-order-trump-0bbae2d2d6f102944f41bb75ad40ce69">Associated Press</a> reported. It&#8217;s unclear whether he meant the government would control the app or another U.S. entity.</p>
<p>The president recently said <a href="https://www.benzinga.com/tech/25/01/43118289/trump-open-to-elon-musk-or-larry-ellison-buying-tiktok-calls-us-permit-key-to-1-trillion-valuation">he was open</a> to a billionaire like <strong>Larry Ellison </strong>or <strong>Elon Musk</strong> buying TiKTok and several interested parties have previously emerged, including a group with "Shark Tank's" <strong>Kevin O'Leary</strong>.</p>
<p>A quick search for TikTok on the Google Play Store brings up the current result: "Looking for TikTok? Downloads for this app are paused due to current US legal requirements."</p>
<p>While TikTok could find its way back on app stores, the sale of phones with one specific app is not new.</p>
<p>As Benzinga previously reported, some owners of iPhones with the mobile game &#8220;Fortnite&#8221; downloaded on them listed their phones for sale on eBay in 2020, as reported by PCMag. The move came after &#8220;Fortnite&#8221; owner Epic Games decided to skirt Apple&#8217;s 30% cut of payments by offering a direct payment option. Apple removed the game from its app store, which kicked off a lengthy battle&nbsp;<a href="https://www.benzinga.com/news/21/05/20947603/epic-games-vs-apple-lawsuit-reveals-just-how-much-money-fortnite-has-made" target="_blank" rel="noreferrer noopener">between the two companies.</a></p>
<p>Users also tried to sell their phones with mobile game &#8220;Flappy Bird&#8221; for high amounts of money back in 2014, as reported by&nbsp;<a href="https://www.pcmag.com/news/flappy-bird-equipped-iphones-selling-for-100k-on-ebay" target="_blank" rel="noreferrer noopener">PCMag</a>. The creator of the hit game pulled it from app stores after it hit number one and saw huge usage. One phone reached a price of $99,900 on eBay before the auction company&nbsp;<a href="https://www.latimes.com/business/technology/la-fi-tn-ebay-99900-iphone-flappy-bird-20140210-story.html" target="_blank" rel="noreferrer noopener">took&nbsp;</a>the listing down.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43117503/marvel-mobile-game-goes-dark-after-tiktok-ban-how-disneys-superhero-brand-got-caught-up-in-us-vs-china-battle"><strong>Marvel Mobile Game Goes Dark After TikTok Ban: How Disney&#8217;s Superhero Brand Got Caught Up In US Vs. China Battle</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Social Media

Tech

AAPL

EBAY

GOOG

GOOGL

TikTok Ban Effect: Smartphones With App Installed Hit Ebay

<p>Ratings for Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Paycom Software, presenting an average target of $208.18, a high estimate of $260.00, and a low estimate of $175.00. This upward trend is evident, with the current average reflecting a 10.63% increase from the previous average price target of $188.18.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666055_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Paycom Software by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$221.00</td>
<td>$229.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$221.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$260.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Jared Levine</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$248.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$196.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$181.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$175.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$197.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paycom Software. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paycom Software compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Paycom Software's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Paycom Software's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PAYC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Paycom Software analyst ratings.</strong></a></p>
<h2>Delving into Paycom Software's Background</h2>
<p>Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.</p>
<h3>Paycom Software's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Paycom Software's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>11.23%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.21%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.07%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Paycom Software's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.88%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Paycom Software's debt-to-equity ratio is below the industry average at <strong>0.06</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PAYC

11 Analysts Assess Paycom Software: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $139.67, a high estimate of $149.00, and a low estimate of $135.00. Witnessing a positive shift, the current average has risen by 1.95% from the previous average price target of $137.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666047_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Abbott Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Abbott Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Abbott Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Abbott Laboratories analyst ratings.</strong></a></p>
<h2>About Abbott Laboratories</h2>
<p>Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.</p>
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>4.85%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Abbott Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>15.48%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Abbott Laboratories's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>4.16%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Abbott Laboratories's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>2.23%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.38</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Abbott Laboratories Stock: Analyst Perspectives (6 Ratings)

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $254.0, a high estimate of $280.00, and a low estimate of $213.00. Highlighting a 1.6% decrease, the current average has fallen from the previous average price target of $258.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666038_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Travelers Companies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$268.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$225.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$213.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$268.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$278.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$278.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$259.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$217.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Robert Farnam</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Neutral</td>
<td>$280.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Travelers Companies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travelers Companies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Travelers Companies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Travelers Companies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Travelers Companies analyst ratings.</strong></a></p>
<h2>Delving into Travelers Companies's Background</h2>
<p>Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance. Travelers derives 6% of its premiums from foreign markets.</p>
<h3>Travelers Companies: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Travelers Companies showcased positive performance, achieving a revenue growth rate of <strong>11.93%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Travelers Companies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>10.5%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Travelers Companies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.76%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Travelers Companies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.95%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Travelers Companies's debt-to-equity ratio surpasses industry norms, standing at <strong>0.29</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Travelers Companies Stock: Analyst Perspectives (9 Ratings)

<p>Ratings for Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.8, a high estimate of $23.00, and a low estimate of $17.00. Marking an increase of 20.58%, the current average surpasses the previous average price target of $17.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666029_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Envista Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Underperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$23.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Envista Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Envista Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Envista Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Envista Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Envista Holdings analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Envista Holdings</h2>
<p>Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products &amp; Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment &amp; Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.</p>
<h3>Unraveling the Financial Story of Envista Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Envista Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-4.8%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Envista Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.36%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Envista Holdings's ROE excels beyond industry benchmarks, reaching <strong>0.27%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Envista Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.15%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Envista Holdings's debt-to-equity ratio is below the industry average. With a ratio of <b>0.51</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVST

5 Analysts Have This To Say About Envista Holdings

<p>In the last three months, 8 analysts have published ratings on BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $45.75, a high estimate of $50.00, and a low estimate of $42.00. Surpassing the previous average price target of $41.00, the current average has increased by 11.59%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666019_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive BankUnited. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BankUnited. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of BankUnited compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for BankUnited's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of BankUnited's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BKU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BankUnited analyst ratings.</strong></a></p>
<h2>All You Need to Know About BankUnited</h2>
<p>BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located primarily throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.</p>
<h3>BankUnited: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> BankUnited's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>5.96%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> BankUnited's net margin excels beyond industry benchmarks, reaching <strong>23.58%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> BankUnited's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.2%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> BankUnited's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> BankUnited's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.53</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BankUnited Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

<p>Throughout the last three months, 16 analysts have evaluated Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Comerica, revealing an average target of $73.75, a high estimate of $85.00, and a low estimate of $64.00. Witnessing a positive shift, the current average has risen by 4.24% from the previous average price target of $70.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737666011_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Comerica. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Comerica. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Comerica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Comerica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Comerica's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comerica analyst ratings.</strong></a></p>
<h2>Get to Know Comerica Better</h2>
<p>With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.</p>
<h3>Financial Milestones: Comerica's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Comerica's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-9.49%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Comerica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.82%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Comerica's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.78%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Comerica's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.97</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

M3-Brigade Acquisition

M3-Brigade Acquisition (MBAVU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga